Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
CNS Drugs
Published in: CNS Drugs 5/2007

01-05-2007 | Original Research Article

Effect of Adjunctive Modafinil on Wakefulness and Quality of Life in Patients with Excessive Sleepiness-Associated Obstructive Sleep Apnoea/Hypopnoea Syndrome

A 12-Month, Open-Label Extension Study

Authors: Dr Max Hirshkowitz, Jed Black

Published in: CNS Drugs | Issue 5/2007

Login to get access

Abstract

Objective: To evaluate the long-term effect on wakefulness, functional status and quality of life and tolerability of adjunctive modafinil in continuous positive airway pressure (CPAP)-treated patients with residual excessive sleepiness (ES) associated with obstructive sleep apnoea/hypopnoea syndrome (OSA/HS).
Study design: 12-month, open-label extension of a 12-week, randomised, double-blind, placebo-controlled study.
Setting: Thirty-seven centres in the US and four in the UK.
Patients: Two hundred and sixty-six patients experiencing ES associated with OSA/HS who completed at least 8 weeks of the 12-week double-blind study, and who received adequate education and intervention efforts to encourage use of nasal CPAP (nCPAP).
Intervention: Patients receiving nCPAP therapy were administered modafinil 200 mg/day during week 1, 300 mg/day during week 2, and then 200, 300 or 400 mg/day, based on the investigator’s assessment of efficacy and tolerability, for the remainder of the study.
Main outcome measures: Assessments included the Epworth Sleepiness Scale (ESS), Functional Outcomes of Sleep Questionnaire (FOSQ) and Short Form-36 Health Survey (SF-36).
Results: One hundred and seventy five patients (66%) completed the study. Modafinil maintained a significant effect on wakefulness, as shown by improvement in the ESS total score at months 3, 6, 9 and 12 compared with baseline (all p < 0.0001). Modafinil also improved functional status (FOSQ total score) and general health (SF-36 mental and physical component scores) at months 6 and 12 compared with baseline (all p < 0.05).
Modafinil was well tolerated. The most common adverse events reported were infection (11.3%), headache (9.4%) and nervousness (9.0%). Serious adverse events were reported in 13 patients, with two of these events (mild bradycardia and severe syncope, both in the same patient) considered to be possibly related to modafinil. There were few clinically meaningful changes in clinical laboratory data, vital signs, physical examination findings or ECG results. Important changes included significant increase in blood pressure in six patients, five of whom had a history of hypertension.
Conclusions: Adjunctive modafinil maintained effects on wakefulness and functional outcomes, and improved quality of life in patients with OSA/HS experiencing residual ES over a 12-month period. Modafinil was well tolerated during long-term therapy.
Footnotes
1
The use of trade names is for product identification purposes only and does not imply endorsement.
 
Literature
1.
Olson EJ, Moore WR, Morgenthaler TI, et al. Obstructive sleep apnea-hypopnea syndrome. Mayo Clin Proc 2003; 78: 1545–52PubMedCrossRef
2.
Young T, Skatrud J, Peppard PE. Risk factors for obstructive sleep apnea in adults. JAMA 2004; 291(16): 2013–6PubMedCrossRef
3.
Young T, Palta M, Dempsey J, et al. The occurrence of sleep-disordered breathing among middle-aged adults. N Engl J Med 1993 1993; 328(17): 1230–5CrossRef
4.
Seneviratne U, Puvanendran K. Excessive daytime sleepiness in obstructive sleep apnea: prevalence, severity, and predictors. Sleep Med 2004; 5: 339–43PubMedCrossRef
5.
Bedard MA, Montplaisir J, Malo J, et al. Persistent neuropsychological deficits and vigilance impairment in sleep apnea syndrome after treatment with continuous positive airways pressure (CPAP). J Clin Exp Neuropsychol 1993; 15: 330–41PubMedCrossRef
6.
Naegele B, Thouvard V, Pepin JL, et al. Deficits of cognitive executive functions in patients with sleep apnea syndrome. Sleep 1995; 18(1): 43–52PubMed
7.
Gliklich RE, Taghizadeh F, Winkelman JW. Health status in patients with disturbed sleep and obstructive sleep apnea. Otolaryngol Head Neck Surg 2000; 122: 542–6PubMedCrossRef
8.
Barbé F, Pericás J, Muñoz A, et al. Automobile accidents in patients with sleep apnea syndrome: an epidemiological and mechanistic study. Am J Respir Crit Care Med 1998; 158: 18–22PubMed
9.
Ulfberg J, Carter N, Edling C. Sleep-disordered breathing and occupational accidents. Scand J Work Environ Health 2000; 26: 237–42PubMedCrossRef
10.
Engleman H, Joffe D. Neuropsychological function in obstructive sleep apnoea. Sleep Med Rev 1999; 3(1): 59–78PubMedCrossRef
11.
Engleman HM, Martin SE, Deary IJ, et al. Effect of continuous positive airway pressure treatment on daytime function in sleep apnoea/hypopnoea syndrome. Lancet 1994; 343: 572–5PubMedCrossRef
12.
Jenkinson C, Davies RJ, Mullins R, et al. Comparison of therapeutic and subtherapeutic nasal continuous positive airway pressure for obstructive sleep apnoea: a randomised prospective parallel trial. Lancet 1999; 353: 2100–5PubMedCrossRef
13.
D’Ambrosio C, Bowman T, Mohsenin V. Quality of life in patients with obstructive sleep apnea: effect of nasal continuous positive airway pressure: a prospective study. Chest 1999; 115: 123–9PubMedCrossRef
14.
Bennett LS, Barbour C, Langford B, et al. Health status in obstructive sleep apnea: relationship with sleep fragmentation and daytime sleepiness, and effects of continuous positive airway pressure treatment. Am J Respir Crit Care Med 1999; 159: 1884–90PubMed
15.
Sforza E, Krieger J. Daytime sleepiness after long-term continuous positive airway pressure (CPAP) treatment in obstructive sleep apnea syndrome. J Neurol Sci 1992; 110: 21–6PubMedCrossRef
16.
Black J, Hirshkowitz M. Modafinil for treatment of residual excessive sleepiness in nasal continuous positive airway pressure-treated obstructive sleep apnea/hypopnea syndrome. Sleep 2005; 28: 464–71PubMed
17.
Pack AI, Black JE, Schwartz JR, et al. Modafinil as adjunct therapy for daytime sleepiness in obstructive sleep apnea. Am J Respir Crit Care Med 2001; 164(9): 1675–81PubMed
18.
Engber TM, Koury EJ, Dennis SA, et al. Differential patterns of regional c-Fos induction in the rat brain by amphetamine and the novel wakefulness-promoting agent modafinil. Neurosci Lett 1998; 241(2–3): 95–8PubMedCrossRef
19.
Lin JS, Hou Y, Jouvet M. Potential brain neuronal targets for amphetamine-, methylphenidate-, and modafinil-induced wakefulness, evidenced by c-fos immunocytochemistry in the cat. Proc Natl Acad Sci U S A 1996; 93(24): 14128–33PubMedCrossRef
20.
Ballon JS, Feifel D. A systematic review of modafinil: potential clinical uses and mechanisms of action. J Clin Psychiatry 2006; 67(4): 554–66PubMedCrossRef
21.
Gallopin T, Luppi PH, Rambert FA, et al. Effect of the wake-promoting agent modafinil on sleep-promoting neurons from the ventrolateral preoptic nucleus: an in vitro pharmacologic study. Sleep 2004; 27(1): 19–25PubMed
22.
Scammell TE, Estabrooke IV, McCarthy MT, et al. Hypothalamic arousal regions are activated during modafinil-induced wakefulness. J Neurosci 2000; 20(22): 8620–8PubMed
23.
Wisor JP, Eriksson KS. Dopaminergic-adrenergic interactions in the wake promoting mechanism of modafinil. Neuroscience 2005; 132(4): 1027–34PubMedCrossRef
24.
de Saint Hilaire Z, Orosco M, Rouch C, et al. Variations in extracellular monoamines in the prefrontal cortex and medial hypothalamus after modafinil administration: a microdialysis study in rats. Neuroreport 2001; 12(16): 3533–7PubMedCrossRef
25.
Kingshott RN, Vennelle M, Coleman EL, et al. Randomized, double-blind, placebo-controlled crossover trial of modafinil in the treatment of residual excessive daytime sleepiness in the sleep apnea/hypopnea syndrome. Am J Respir Crit Care Med 2001; 163(4): 918–23PubMed
26.
Johns MW. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep 1991; 14(6): 540–5PubMed
27.
Weaver TE, Laizner AM, Evans LK, et al. An instrument to measure functional status outcomes for disorders of excessive sleepiness. Sleep 1997; 20(10): 835–43PubMed
28.
29.
Dinges DF, Weaver TE. Effects of modafinil on sustained attention performance and quality of life in OSA patients with residual sleepiness while being treated with nCPAP. Sleep Med 2003; 4(5): 393–402PubMedCrossRef
30.
Schwartz JR, Hirshkowitz M, Erman MK, et al. Modafinil as adjunct therapy for daytime sleepiness in obstructive sleep apnea: a 12-week, open-label study. Chest 2003; 124(6): 2192–9PubMedCrossRef
31.
Beusterien KM, Rogers AE, Walsleben JA, et al. Health-related quality of life effects of modafinil for treatment of narcolepsy. Sleep 1999; 22(6): 757–65PubMed
32.
Engleman HM, Martin SE, Douglas NJ. Compliance with CPAP therapy in patients with the sleep apnoea/hypopnoea syndrome. Thorax 1994; 49: 263–6PubMedCrossRef
33.
Reeves-Hoche MK, Meck R, Zwillich CW. Nasal CPAP: an objective evaluation of patient compliance. Am J Respir Crit Care Med 1994; 149: 149–54PubMed
34.
Krieger J. Long-term compliance with nasal continuous positive airway pressure (CPAP) in obstructive sleep apnea patients and nonapneic snorers. Sleep 1992; 15(6 Suppl.): S42–6PubMed
35.
Pieters T, Collard P, Aubert G, et al. Acceptance and long-term compliance with nCPAP in patients with obstructive sleep apnoea syndrome. Eur Respir J 1996; 9(5): 939–44PubMedCrossRef
36.
Marin JM, Carrizo SJ, Vicente E, et al. Long-term cardiovascular outcomes in men with obstructive sleep apnoea-hypopnoea with or without treatment with continuous positive airway pressure: an observational study. Lancet 2005; 365(9464): 1046–53PubMed
37.
Schiza SE, Fraggedaki A, Basta M, et al. The use of modafinil in patients with obstructive apnea hypopnea syndrome: a randomized, placebo-controlled, double-blind study. Sleep 2001; 24 Suppl.: A10–1
38.
Peppard PE, Young T, Palta M, et al. Prospective study of the association between sleep-disordered breathing and hypertension. N Engl J Med 2000; 342(19): 1378–84PubMedCrossRef
39.
Nieto FJ, Young TB, Lind BK, et al. Association of sleep-disordered breathing, sleep apnea, and hypertension in a large community-based study. JAMA 2000; 283: 1829–36PubMedCrossRef
40.
Shamsuzzaman AS, Gersh BJ, Somers VK. Obstructive sleep apnea: implications for cardiac and vascular disease. JAMA 2003; 290: 1906–14PubMedCrossRef
41.
Heitmann J, Cassel W, Grote L, et al. Does short-term treatment with modafinil affect blood pressure in patients with obstructive sleep apnea? Clin Pharmacol Ther 1999; 65(3): 328–35PubMedCrossRef
Metadata
Title
Effect of Adjunctive Modafinil on Wakefulness and Quality of Life in Patients with Excessive Sleepiness-Associated Obstructive Sleep Apnoea/Hypopnoea Syndrome
A 12-Month, Open-Label Extension Study
Authors
Dr Max Hirshkowitz
Jed Black
Publication date
01-05-2007
Publisher
Springer International Publishing
Published in
CNS Drugs / Issue 5/2007
Print ISSN: 1172-7047
Electronic ISSN: 1179-1934
DOI
https://doi.org/10.2165/00023210-200721050-00004

Other articles of this Issue 5/2007

CNS Drugs 5/2007 Go to the issue

Adis Drug Profile

Pramipexole

Adis Drug Profile

Paliperidone Extended Release

Adis Drug Profiles

Paliperidone Extended Release

Adis Drug Profile

Pramipexole

Review Article

Use of Non-Benzodiazepine Hypnotics in the Elderly

Adis Drug Profile

Pramipexole